Dismantling cost and infrastructure barriers to equitable access to gene therapies for sickle cell disease

Lancet Haematol. 2024 Aug;11(8):e556-e559. doi: 10.1016/S2352-3026(24)00175-3. Epub 2024 Jul 1.

Authors

Akshay Sharma¹, Tami D John²

Affiliations

¹ Department of Bone Marrow Transplantation and Cellular Therapy, St Jude Children's Research Hospital, Memphis, TN 38105, USA. Electronic address: [email protected].
² Department of Pediatrics, Hematology, Oncology, Stem Cell, and Regenerative Medicine, Stanford University, Palo Alto, CA, USA.

PMID: 38964356
DOI: 10.1016/S2352-3026(24)00175-3

No abstract available

MeSH terms

Anemia, Sickle Cell* / economics
Anemia, Sickle Cell* / therapy
Genetic Therapy* / economics
Genetic Therapy* / methods
Health Services Accessibility* / economics
Humans